Sarepta Therapeutics (SRPT) 10-Q2012 Q1 Quarterly report

Filed: 10 May 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: aftermath, aimed, attack, avoid, billion, binding, biodefense, BioShield, bioterrorist, broader, case, cited, civilian, compel, competitor, component, compulsory, constrained, created, curtail, customer, decade, deciding, decision, depleting, element, endpoint, enhance, environment, EP, evolving, exacerbate, forced, GLP, heading, IIb, incentivized, inconsequential, incremental, inThe, JP, Lancet, lethal, letter, live, lived, marginal, matter, midst, national, noncash, notified, notifying, NS, nuclear, path, paused, percentage, political, pursue, radiological, regain, regained, reliant, reorganization, replenish, resist, responsive, restructured, restructuring, revaluation, rough, route, royalty, sector, sequestration, shorter, single, Subpart, succeeded, suggesting, Tekmira, threaten, tolerated, top, transfer, uncertainty, unclear, unfavorable, untested, viability, warfighter, weekly, widespread

Removed: Acceleron, account, accrual, addin, agent, agreed, amendment, Anthrax, average, avian, base, behavior, Boyle, chemistry, commensurate, compatibility, correlate, countering, David, deadly, delivery, Dengue, departure, description, designated, dividend, DTRA, employ, enable, enabling, ending, enrolled, equal, estimated, executed, exercisable, exhibited, expend, expired, flu, formulation, generation, half, Host, infrequently, intended, intranasal, Investigational, Kingdom, life, lifted, lump, marketed, method, milestone, modifying, morpholino, nonrecurring, objective, offering, opposing, organizational, partial, pathway, Paul, permanent, placement, prevailing, randomized, rate, relief, remaining, removed, renumbered, requiring, reserved, Ricin, satisfied, seasonal, selectively, separation, September, settle, spectrum, strain, strong, sublease, sum, swine, systemically, Tamiflu, technical, tested, TMT, traded, traditional, treasury, unprofitable, unvested, version, wasting, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SRPT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

I, Christopher Garabedian, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report of AVI BioPharma, Inc. on Form 10-Q for the quarterly period ended March 31, 2012, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of AVI BioPharma, Inc.


May 10, 2012				/s/ Christopher Garabedian
				Christopher Garabedian,
				President and Chief Executive Officer
				(Principal Executive and Financial Officer)

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to AVI BioPharma, Inc. and will be retained by AVI BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by AVI BioPharma, Inc. for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that AVI BioPharma, Inc. specifically incorporates it by reference.